Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HepTcell
- Development stage
- Discontinued
- Lead developer
- Altimmune
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**HepTcell** is an investigational therapeutic vaccine for chronic hepatitis B developed from the FP-02.2 program. It consists of nine synthetic peptides representing conserved hepatitis B virus sequences and is formulated with IC31, a Toll-like receptor 9 based adjuvant. The vaccine was designed to restore HBV-specific T-cell responses, overcome immune tolerance, and support a functional cure defined by loss of circulating hepatitis B surface antigen. Altimmune evaluated HepTcell in Phase 1 and Phase 2 studies, but ended further development after the Phase 2 program showed insufficient overall efficacy to justify advancement. ([ir.altimmune.com](https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-ind-clearance-phase-2-trial-heptcelltm))
- Brand names
- HepTcell
- Other names
- FP-02.2FP02.2FP 02.2adjuvanted FP-02.2
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on HepTcell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HepTcell.